Perception neuroscience initiates phase 2a study of pcn-101 (r-ketamine) for treatment resistant depression

New york and berlin, sept. 14, 2021 (globe newswire) -- perception neuroscience (perception), an atai life sciences (atai) biopharmaceutical company focused on developing innovative therapies in neuropsychiatric diseases, today announced the initiation of a phase 2a clinical study to evaluate the safety and efficacy of pcn-101 (r-ketamine). r-ketamine is a stereoisomer of ketamine being developed for therapeutic treatment of psychiatric disorders such as treatment resistant depression (trd). the phase 2a clinical trial has received the necessary regulatory and ethics approvals to initiate the study.
ATAI Ratings Summary
ATAI Quant Ranking